Proof-of-Concept, Calcium Aluminosilicate Anti-Diarrheal (CASAD) for Treatment of Clostridium Difficile Infection
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01570634|
Recruitment Status : Terminated (Study was stopped for slow enrollment - only 2 patients, no evaluable results)
First Posted : April 4, 2012
Results First Posted : March 8, 2013
Last Update Posted : March 8, 2013
Clostridium difficile (C. difficile) can cause symptoms ranging from mild diarrhea to life-threatening colitis. Illness from C. difficile most commonly affects patients in hospitals and long-term care facilities and typically occurs after a patient has received antibiotics.
In vitro data indicate Calcium Aluminosilicate Anti-Diarrheal (CASAD) has the potential to bind TNFα, IL-1, IL-6, and IL-10 in the intestines and, therefore, may act to reduce severity of fever, leukocytosis, and bowel injury in patients with C. difficile infection. This would likely occur in conjunction with neutralization of C. difficile toxins A&B by CASAD. Computer modeling of CASAD performed by Phillips et al. at Texas A&M University supports this hypothesis.
The investigators hypothesize that adding CASAD 1.5 grams po tid to any standard-of-care therapy will reduce the duration and severity of diarrhea and other symptoms in patients with C. difficile infection.
|Condition or disease||Intervention/treatment||Phase|
|Diarrhoea, Clostridium Difficile||Drug: Calcium Aluminosilicate Anti-Diarrheal (CASAD)||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||2 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Proof-of-Concept, CASAD for Treatment of Clostridium Difficile Infection|
|Study Start Date :||March 2012|
|Actual Primary Completion Date :||September 2012|
|Actual Study Completion Date :||September 2012|
Experimental: Open Label CASAD
Treatment with CASAD for 14 days
Drug: Calcium Aluminosilicate Anti-Diarrheal (CASAD)
CASAD 3 500mg capsules po tid for 14 days with 4 weeks of follow up
Other Name: CASAD
- Resolution of Diarrhea [ Time Frame: 42 days ]To evaluate the safety and efficacy of CASAD added to the standard-of-care for the therapy of Clostridium difficile infection (C. difficile).
- Stools Per Day [ Time Frame: 14 days ]Compare the number of liquid stools per day during treatment period
- Resolution of Abdominal Pain [ Time Frame: 14 days ]Compare time to resolution of abdominal pain
- Absence of Relapse [ Time Frame: 42 days ]Compare sustained clinical response
- Side-effects and Complications [ Time Frame: 42 days ]Compare side-effects and complications
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01570634
|United States, Texas|
|Scott & White Memorial Hospital|
|Temple, Texas, United States, 76508|
|Principal Investigator:||Aarthi Narasimhan, MD||Scott & White Memorial Hospital|